Abstracts thetical cohort of patients diagnosed with RRMS in the United States (US). Health states were based on the Kurtzke expanded disability status scale (EDSS) (higher EDSS scores = increased disease severity). Relapse and disease progression transition probabilities for SMA were obtained from natural history studies. Treatment effects of the immunomodulatory therapies were estimated by applying a percent reduction to the SMA transition probabilities and adjusting for neutralizing antibodies (NAbs) and treatment discontinuation. Therapy-specific data was obtained from clinical trials and long-term follow-up studies. Transitions among health states occurred in 1-month cycles for the lifetime of a patient. Costs (2005US$) and outcomes were discounted at 3% annually. RESULTS: The incremental cost per quality-adjusted life-year (QALY) is $258, 465, $303,008, $395,686, and $310,691 for SCGA, IM-IFNb1-a, SC-IFNb1-a and SC-IFNb1-b compared to SMA respectively. Sensitivity analyses showed results were sensitive to changes in utilities, disease progression rates, time horizon and immunomodulatory therapy cost. CONCLUSIONS: Model results indicated that the immunomodulatory therapies are both more effective and more costly than SMA in treating RRMS. Although the reported incremental cost-effectiveness ratios (ICERs) are well above $50,000/QALY, not all economic evaluations are bounded by this threshold and numerous interventions with ICERs above this threshold have been deemed valuable by patients, health care decision-makers and society. This model suggests that of the immunomodulatory therapies for MS SCGA is the most cost-effective. Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3 Tufts University School of Medicine, Boston, MA, USA OBJECTIVES: To estimate the cost-effectiveness of topiramate (TPM) treatment for migraine prevention versus no preventive treatment using newly available efficacy and cost data. METHODS: Model inputs included baseline migraine days per month (base-case: 7), treatment discontinuation, treatment response, cost of preventive therapy, cost of acute treatment per attack (medical and pharmacy services), hours of work lost per attack, and hourly wage. Model outcomes were expressed monthly and included the number of migraine days averted, disability hours, total cost of preventive and acute treatment, and lost wages. Model inputs were gathered from published literature, clinical studies of TPM in migraine prevention (doubleblind and open-label extensions), and census data. Unit costs for resource use were obtained by analyzing actual payments of year 2004 medical claims from a large managed care database. RESULTS: TPM treatment was associated with a mean reduction in migraine days of 2.4/month, and 6.5 fewer disability hours. Acute treatment costs per patient per month (including pharmacy and medical) were $39 lower ($100 versus $139) and work loss was $65 lower ($125 versus $190) for TPM preventive arm. The incremental monthly cost per patient of TPM preventive therapy was $109. Consequently, the total cost in TPM arm was $5 higher than in no-preventive arm ($109-$39-$65); incremental total cost per migraine day averted was $2 for TPM versus no preventive therapy. Results are sensitive to the baseline migraine rate: as the rate increases, total cost of care decreases, with break-even at 7.4 migraine days/month. CONCLUSIONS: Economic savings (direct and indirect costs) associated with lower migraine frequency offset approximately 93% of the cost of preventive therapy, suggesting that TPM is a cost-effective treatment for migraine prevention.
Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3 Tufts University School of Medicine, Boston, MA, USA OBJECTIVES: To estimate the cost-effectiveness of topiramate (TPM) treatment for migraine prevention versus no preventive treatment using newly available efficacy and cost data. METHODS: Model inputs included baseline migraine days per month (base-case: 7), treatment discontinuation, treatment response, cost of preventive therapy, cost of acute treatment per attack (medical and pharmacy services), hours of work lost per attack, and hourly wage. Model outcomes were expressed monthly and included the number of migraine days averted, disability hours, total cost of preventive and acute treatment, and lost wages. Model inputs were gathered from published literature, clinical studies of TPM in migraine prevention (doubleblind and open-label extensions), and census data. Unit costs for resource use were obtained by analyzing actual payments of year 2004 medical claims from a large managed care database. RESULTS: TPM treatment was associated with a mean reduction in migraine days of 2.4/month, and 6.5 fewer disability hours. Acute treatment costs per patient per month (including pharmacy and medical) were $39 lower ($100 versus $139) and work loss was $65 lower ($125 versus $190) for TPM preventive arm. The incremental monthly cost per patient of TPM preventive therapy was $109. Consequently, the total cost in TPM arm was $5 higher than in no-preventive arm ($109-$39-$65); incremental total cost per migraine day averted was $2 for TPM versus no preventive therapy. Results are sensitive to the baseline migraine rate: as the rate increases, total cost of care decreases, with break-even at 7.4 migraine days/month. CONCLUSIONS: Economic savings (direct and indirect costs) associated with lower migraine frequency offset approximately 93% of the cost of preventive therapy, suggesting that TPM is a cost-effective treatment for migraine prevention.
PNL10 COST-EFFECTIVENESS OF MS DISEASE MODIFYING AGENTS: A MARKOV AND VALUE OF INFORMATION ANALYSIS
Lundy J, Coons SJ University of Arizona, Tucson, AZ, USA OBJECTIVES: A new disease modifying agent for the treatment of MS, natalizumab (Tysabri), was introduced to the market at the end of 2004 and withdrawn in early 2005 because of two cases (one fatal) of progressive multifocal leukoencephalopathy (PML). In the event that natalizumab is reintroduced to the market, the present study was conducted to assess the costeffectiveness of natalizumab compared to interferon beta-1a (Avonex) and no treatment. Expected value of perfect information (EVPI) and partial EVPI (PEVPI) analyses were conducted to characterize the existing uncertainty in the model parameters.
METHODS:
The main analytical technique used in this study was incremental cost-effectiveness analysis using a Markov model. Two-level Monte Carlo simulations were performed to obtain the EVPI and PEVPI estimates. Health care costs were derived from the literature. The Disability Status Scale (DSS) was used as the measure of disability; utility values were assigned to the 10 DSS disability states based on data from the literature. Cost valuations were based on the direct health-care costs associated with disease relapse and medical care in each disability state expressed in 2005 US dollars. RESULTS: The Markov cohort analysis returned the following costs and QALYs: No Treatment-$175,790 and 30.971 QALYs; interferon beta-1a-$830,861 and 34.391 QALYs; natalizumab-$1,076,327 and 34.497 QALYs. The incremental cost-effectiveness ratios for interferon beta-1a and natalizumab compared to no treatment were: interferon beta-1a-$191,541 per QALY gained; natalizumab-$255,399 per QALY gained. CONCLUSIONS: Model inputs were based on a limited number of available studies and the results should be interpreted with caution. Nevertheless, the results of this preliminary analysis suggest that treatment with interferon beta-1a is somewhat more cost-effective than natalizumab. The value of information results indicate that more information about the transition probabilities and QALY parameters are necessary to reduce the uncertainty in the model. (DMAs) . With the introduction of Medicare Part D and in the presence of substantial variation in analytical methods used to examine cost-effectiveness (CE) of MS DMAs, an assessment of the models' features and parameters is necessary to understand and interpret the CE results for clinical practice and health policy. This study compares the results of CE models evaluating DMAs (interferon beta-1a, interferon beta-1b,
PNL11 COMPARING APPLES WITH WHAT: DIFFERENT INPUTS AND ASSUMPTIONS PRODUCE DIFFERENT CONCLUSIONS IN MS ECONOMIC MODELS
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